{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T22:15:17Z","timestamp":1649801717232},"reference-count":48,"publisher":"Akademiai Kiado Zrt.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Microbiologica et Immunologica Hungarica"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1556\/amicr.60.2013.4.1","type":"journal-article","created":{"date-parts":[[2013,11,30]],"date-time":"2013-11-30T02:01:40Z","timestamp":1385776900000},"page":"379-396","source":"Crossref","is-referenced-by-count":3,"title":["Varicella-zoster virus vaccine, successes and difficulties"],"prefix":"10.1556","volume":"60","author":[{"given":"Julia","family":"Sarkadi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1086\/522125","article-title":"The safety profile of varicella vaccine: A 10-year review","volume":"197","author":"Galea S.A.","year":"2008","journal-title":"J Inf Dis"},{"key":"2","doi-asserted-by":"crossref","first-page":"e744","DOI":"10.1542\/peds.2008-0567","article-title":"Varicella prevention in the United States: A review of successes and challenges","volume":"122","author":"Marin M.","year":"2008","journal-title":"Pediatrics"},{"key":"3","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.1086\/522129","article-title":"Strategies for zoster vaccination in immunocompromised patients","volume":"197","author":"Cohen J.I.","year":"2008","journal-title":"J Infect Dis"},{"key":"4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1086\/653605","article-title":"Zoster vaccine: Current status and future prospects","volume":"51","author":"Oxman M.N.","year":"2010","journal-title":"Clin Infect Dis"},{"key":"5","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1365-2796.2011.02359.x","article-title":"Efficacy of live zoster vaccine in preventing zoster and postherpetic neuralgia","volume":"269","author":"Gilden D.","year":"2011","journal-title":"J Intern Med"},{"key":"6","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1146\/annurev.med.59.061606.095540","article-title":"Herpes simplex: Insights on pathogenesis and possible vaccines","volume":"59","author":"Koelle D.M.","year":"2008","journal-title":"Annu Rev Med"},{"key":"7","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1586\/erv.09.60","article-title":"New con-cepts in herpes simplex virus vaccine development: Notes from the battlefield","volume":"8","author":"Dasgupta G.","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"8","doi-asserted-by":"crossref","first-page":"4600","DOI":"10.1172\/JCI57148","article-title":"HSV-2: In pursuit of a vaccine","volume":"121","author":"Johnston C.","year":"2011","journal-title":"J Clin Invest"},{"key":"9","unstructured":"Chentoufi, A.A., Kritzer, E., Yu, D.M., Nesburn, A.B., BenMohamed, L.: Towards a ratio-nal design of an aymptomatic clinical herpes vaccine: The old, the new and the unknown. Clin Dev Immunol <b>2012<\/b>, Article ID 187585 (2012)."},{"key":"10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.virol.2012.10.006","article-title":"Varicella zoster vaccines and their implications for development of HSV vaccines","volume":"435","author":"Gershon A.A.","year":"2013","journal-title":"Virology"},{"key":"11","volume-title":"Fields Virology","author":"Roizman B.","year":"2007"},{"key":"12","volume-title":"Fields Virology","author":"Cohen J.I.","year":"2007"},{"key":"13","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ncl.2008.03.011","article-title":"Varicella zoster virus infection: Clinical features, molecular pathogeneis of diseases, and latency","volume":"26","author":"Mueller N.H.","year":"2008","journal-title":"Neurol Clin"},{"key":"14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2217\/14796708.4.1.103","article-title":"Clinical and molecular aspects of varicella zoster virus infection","volume":"4","author":"Gilden D.","year":"2009","journal-title":"Future Neurol"},{"key":"15","first-page":"S13","article-title":"Herpes zoster pathogenesis and cell-mediated immunity and immuno-senescence","volume":"109","author":"Oxman M.N.","year":"2009","journal-title":"J Am Osteopath Assoc"},{"key":"16","first-page":"1323","article-title":"\u00dcber den aetiologischen Zusammenhang der Varizellen mit gewissen F\u00e4llen von Herpes zoster","volume":"22","author":"Bokay J.","year":"1909","journal-title":"Wien Klin Woch"},{"key":"17","doi-asserted-by":"crossref","first-page":"8411","DOI":"10.1128\/JVI.78.16.8411-8420.2004","article-title":"Herpes simplex virus 1 ha multiple mechanisms for blocking virus-induced interferon production","volume":"78","author":"Melroe G.T.","year":"2004","journal-title":"J Virol"},{"key":"18","doi-asserted-by":"crossref","first-page":"8950","DOI":"10.1128\/JVI.73.11.8950-8957.1999","article-title":"Herpes simplex virus inhib-its apoptosis through the action of two genes, US5 and US3","volume":"73","author":"Jerome K.R.","year":"1999","journal-title":"JVirol"},{"key":"19","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1126\/science.287.5457.1500","article-title":"Virus-induced neuronal apoptosis blocked by the herpes simplex virus latency-associated transcript","volume":"287","author":"Perng G.C.","year":"2000","journal-title":"Science"},{"key":"20","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/375415a0","article-title":"A viral inhibitor of peptide transporters for antigen presentation","volume":"375","author":"Fruh K.","year":"1995","journal-title":"Nature"},{"key":"21","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/82_2010_41","article-title":"Varicella zoster virus immune evasion strategies","volume":"342","author":"Abendroth A.","year":"2010","journal-title":"Current Topics inMicrobiology and Immunology"},{"key":"22","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S0140-6736(74)90144-5","article-title":"Live vaccine used to prevent the spread of varicella in children in hospital","volume":"304","author":"Takahashi M.","year":"1974","journal-title":"Lancet"},{"key":"23","first-page":"791","article-title":"Recommendations for the use of live attenuated varicella vaccine","volume":"95","year":"1995","journal-title":"Pediatrics"},{"key":"24","first-page":"1","article-title":"Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"45","year":"1996","journal-title":"Morb Mort Wkly Rep"},{"key":"25","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1006\/viro.2001.0918","article-title":"Varicella vaccine: Genesis, efficacy, and attenuation","volume":"284","author":"Arvin A.M.","year":"2001","journal-title":"Virology"},{"key":"26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1086\/522132","article-title":"Development of varicella vaccine","volume":"197","author":"Takahashi M.","year":"2008","journal-title":"J Infect Dis"},{"key":"27","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1542\/peds.2010-3385","article-title":"Near elimination of varicella deaths in the US after implementation of the vaccination program","volume":"128","author":"Marin M.","year":"2011","journal-title":"Pediatrics"},{"key":"28","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0022-3476(89)80598-0","article-title":"Placebo-controlled trial of varicella vaccine given with or after measles-mumps-rubella vaccine","volume":"114","author":"Englund J.A.","year":"1989","journal-title":"J Pediatr"},{"key":"29","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/1096-9071(200008)61:4<497::AID-JMV13>3.0.CO;2-2","article-title":"OKA varicella vaccine is distinguishable from its parental virus in DNA sequence of open reading frame 62 and its transactivation activity","volume":"61","author":"Gomi Y.","year":"2000","journal-title":"New Med Virol"},{"key":"30","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1086\/315335","article-title":"Nucleotide sequences that distinguish Oka vaccine from parental Oka and other varicella-zoster virus isolates","volume":"181","author":"Argaw T.","year":"2000","journal-title":"J Inf Dis"},{"key":"31","doi-asserted-by":"crossref","first-page":"11023","DOI":"10.1128\/JVI.00777-08","article-title":"Complete DNA sequences of two OKA strain varicella-zoster virus genomes","volume":"82","author":"Tillieux S.L.","year":"2008","journal-title":"J Virol"},{"key":"32","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1056\/NEJM199111283252204","article-title":"The incidence of zoster after immu-nization with live attenuated varicella vacine. A study in children with leukemia","volume":"325","author":"Hardy I.","year":"1991","journal-title":"N Eng J Med"},{"key":"33","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00006454-200002000-00020","article-title":"Herpes zoster in healthy children immunized with varicella vaccine","volume":"19","author":"Takamaya N.","year":"2000","journal-title":"Pediatr Infect Dis J"},{"key":"34","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa013441","article-title":"Use of an inactivated varicella vaccine in recipients of hematopoetic-cell-transplants","volume":"347","author":"Hata A.","year":"2002","journal-title":"N Eng J Med"},{"key":"35","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jcv.2013.01.015","article-title":"Varicella immunity in vaccinated healthcare workers","volume":"57","author":"Behrman A.","year":"2013","journal-title":"J Clin Virol"},{"key":"36","volume-title":"Vaccines and Preventable diseases: Varicella (chickenpox) vaccination","year":"2012"},{"key":"37","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1016\/S0264-410X(02)00180-9","article-title":"Exposure to varicella boosts immu-nity to herpes-zoster: Implications for mass vaccination against chickenpox","volume":"20","author":"Brisson M.","year":"2002","journal-title":"Vaccine"},{"key":"38","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1001\/jama.296.2.157","article-title":"FDA approves shingles vaccine: Herpes zoster vaccine targets older adults","volume":"296","author":"Mitka M.","year":"2006","journal-title":"JAMA"},{"key":"39","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"Shingles prevention study group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman M.N.","year":"2005","journal-title":"N Eng J Med"},{"key":"40","first-page":"1","article-title":"Prevention of herpes zoster. Recommendation of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","author":"Harpaz R.","year":"2008","journal-title":"Center for Disease Control and Prevention, Recommendations and Reports"},{"key":"41","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/cid\/cir970","article-title":"Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50\u201359 years","volume":"54","author":"Schmader K.E.","year":"2012","journal-title":"Clin Infect Dis"},{"key":"42","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.cell.2004.11.007","article-title":"Mannose 6-phosphate receptor dependence of varicella zoster virus infection in vitro and in the epidermis during varicella and zoster","volume":"119","author":"Chen J.J.","year":"2004","journal-title":"Cell"},{"key":"43","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1126\/science.330.6002.304","article-title":"Painful failure of promising genital herpes vaccine","volume":"330","author":"Cohen J.","year":"2010","journal-title":"Science"},{"key":"44","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1517\/14712598.1.3.401","article-title":"Development of a cytomegalovirus vaccine: Lessons from recent clinical trials","volume":"1","author":"Gonczol E.","year":"2001","journal-title":"Expert Opin Biol Ther"},{"key":"45","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1038\/nm1209","article-title":"Vaccines: Past, present and future","volume":"11","author":"Plotkin S.A.","year":"2005","journal-title":"Nature Med"},{"key":"46","doi-asserted-by":"crossref","first-page":"514","DOI":"10.2174\/187152611797636695","article-title":"Vaccines for cytomegalovirus","volume":"11","author":"Bernstein D.I.","year":"2011","journal-title":"Infect Disord Drug Targets"},{"key":"47","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.vaccine.2012.10.074","article-title":"Desirability and feasibility of a vaccine against cytomegalovirus","volume":"31","author":"Griffiths P.","year":"2013","journal-title":"Vaccine"},{"key":"48","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1016\/j.vaccine.2013.03.008","article-title":"Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18\u201364 years of age","volume":"31","author":"Gorse G.J.","year":"2013","journal-title":"Vaccine"}],"container-title":["Acta Microbiologica et Immunologica Hungarica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.akademiai.com\/doi\/pdf\/10.1556\/amicr.60.2013.4.1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T02:30:30Z","timestamp":1597113030000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/doi\/10.1556\/amicr.60.2013.4.1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["10.1556\/AMicr.60.2013.4.1"],"URL":"https:\/\/doi.org\/10.1556\/amicr.60.2013.4.1","relation":{},"ISSN":["1217-8950","1588-2640"],"issn-type":[{"value":"1217-8950","type":"print"},{"value":"1588-2640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}